Notably, a phase II study (NCT03931291) investigating this combination as post-transplant maintenance therapy in TP53-mutated AML/MDS patients demonstrated encouraging relapse-free survival (RFS) and overall survival (OS) outcomes in this high-risk population, with good tolerability [39]. This evidence concerns the gene TP53 and acute myeloid leukemia.